RxDoctor Payments Data

Randall Tibbs

Foot Surgery · Huntsville, ALNPI 1376561787

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Ortho Dermatologics, A Division Of Bausch Health US, LLC at 28.8% of the total. Reporting peaked in 2020 at $490 and has fallen 84.2% since, to $77 in 2025.

$1,577in general payments, 2019–2025

Across 82 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$455
  • Musculoskeletal Transplant Foundation Inc.$228
  • Amgen$167
  • Paratek Pharmaceuticals, Inc.$143
  • Organogenesis Inc.$84
  • Kowa Pharmaceuticals America, Inc.$80
  • plus $420 from 12 others

What the payments were for

  • Food & beverage$1,577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,577 in reported general payments places this provider in the 65th percentile of 35 foot surgery providers in Alabama.

See all foot surgery providers in Alabama

Medicare billing

Part B allowed, 2024
$49,106
Medicare patients
254
Services billed
628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole15$11,068
CiclopiroxCiclopirox Olamine33$724
Gabapentin52$705
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25$206
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$146
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$103
Cephalexin34$100
Diazepam29$36
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$31
Prednisone14$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$455$11,06815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 35 foot surgery providers in Alabama.

Other foot surgery in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →